Momenta Pharmaceuticals, Inc. (MNTA): Improved Fc-mediated Effector Functions...

Reply Private New

Next 10 Prev Next

Send PM Follow Ignore

Followers	22
Posts	3693
Boards Moderated	0
Alias Born	07/20/2006

floblu14

Re: None

Tuesday, 04/02/2019 2:06:55 PM

Tuesday, April 02, 2019 2:06:55 PM

Improved Fc-mediated Effector Functions By An Anti-CTLA-4 Multivalent Fc Agent - 2 April 2019

AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) 2019 Annual Meeting

MNTA Poster Summary:

Anti-CTLA-4 SIFbody shows more than 100-fold increase in binding to human Fc?Rs as compared to ipilimumab.

Fc multimerization does not affect binding to target CTLA-4 or alter the blocking function to CTLA-4.

Anti-CTLA-4 SIFbody induces enhanced ADCC, ADCP and CDC activity in human CTLA-4-transfected cells as compared to ipilimumab and to an afucosylated anti-CTLA-4 mAb.

Anti-CTLA-4 SIFbody induces enhanced ADCC in Treg cells as compared to ipilimumab and to an afucosylated anti-CTLA-4 mAb.

Anti-CTLA-4 SIFbody induces enhanced ADCP in Treg cells as compared to ipilimumab.

Fc multimerization technology applied to an anti-CTLA-4 mAb significantly improves Fc-dependent immune- mediated cytotoxicity and suggest that anti-CTLA-4 SIFbody may represent an optimized novel product to deplete intratumoral Tregs and enhance anti-tumor activity.

Read more:
http://ir.momentapharma.com/static-files/3a3bb59c-3e4e-4f78-9205-b9a7d22e485d